SGD Pharma plots €37 million post Covid-19 expansion

Published 23rd April, 2020 by Greg Morris

The Saint-Quentin-Lamotte plant

French pharmaceutical glass manufacturer SGD Pharma is plotting a €37 million investment at two sites, reports www.lesechos.fr

It is accelerating the implementation of its 2020 investment plan ahead of what it perceives as extended demand from the health sector in the post Covid-19 world.

The investment will be injected in its Saint-Quentin-Lamotte (Somme) and Sucy-en-Brie (Val-de-Marne), glassworks.

It will expand its second furnace at its Sucy facility, equipping its hot end with forming machines to deal with the requirements of post-epidemic production, as well as developing its control capabilities in the cold end.

Work is planned to start in June.

Source : Les Echos, 22 avril 2020, www.lesechos.fr

Greg Morris

Glass International Editor

Greg Morris has been editor of Glass International and organiser of the Glassman conferences since 2012, specialising in glass packaging. Prior to this he spent five years working in newspaper journalism.